Dr Amritha Nair

Industry Partnerships and Commercialisation Senior Executive, Faculty of Medicine

Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property; marketing of technologies primed for commercialisation and supporting commercialisation via licensing or spinouts. Amritha also supports researchers in their bids for access to translational funding. Amritha manages an extensive IP portfolio, mainly focussed on therapeutics and diagnostics.

Prior roles include innovation consulting for small and medium enterprises and handling the drug development and start-up activities for a private equity backed life science development group in Houston, USA.

Amritha has a PhD in Molecular and Human Genetics from Baylor College of Medicine, Houston, USA and a MSc in Human Genetics from Sri Ramachandra University, Chennai, India.

Amritha's portfolio

Oligonucleotide Suppression Of Let-7 Binding By H19 To Reduce Sensitivity To Inflammation

Oligonucleotide Suppression Of Let-7 Binding By H19 To Reduce Sensitivity To Inflammation

novel oligonucleotides that bind to H19, displacing Let-7 miRNAs, leading to a reduction in inflammation in muscle tissues, and consequently a reduction in muscle wasting. Find out more

Media for the growth of Lactobacillus Iners

Media for the growth of Lactobacillus Iners

A novel growth medium for the culture of Lactobacillus iners to unprecedented high cell densities within 24 hours. Find out more

Use of Capsaicin/TRPV1 agonists for prevention of diabetic foot ulcers

Use of Capsaicin/TRPV1 agonists for prevention of diabetic foot ulcers

Topical use of Capsaicin or TRPV 1 agonists for the prevention of diabetic ulcers in a patient suffering from diabetic peripheral neuropathy (DPN). Find out more

Wide clip and applicator for minimally invasive surgery

Wide clip and applicator for minimally invasive surgery

A new minimally invasive surgical instrument - a rotative surgical clip and applicator that allows the clamping of large anatomical areas for use in minimally invasive surgery. Find out more

Methods to scale production of hPSC-derived endothelial cells

Methods to scale production of hPSC-derived endothelial cells

A new 3D-culture methodology using stirred-tank bioreactors as a scalable platform for the production of hPSC-derived endothelial cells Find out more

Human monoclonal antibodies to COVID-19

Human monoclonal antibodies to COVID-19

A suite of broad neutralising monoclonal antibodies (bnMABs) isolated to be used for treatment of coronaviruses with a focus on SARS-CoV-2 (2019-nCoV). Find out more

First-in-class drug candidate for treatment of multiple myeloma and Diffuse Large B Cell Lymphoma

First-in-class drug candidate for treatment of multiple myeloma and Diffuse Large B Cell Lymphoma

DTP3 is a first-in-class GADD45β/MKK7 inhibitor targeting the NF-κB pathway Find out more

Two distinct late stage preclinical lead series of highly specific inhibitors of MAP4K4

Two distinct late stage preclinical lead series of highly specific inhibitors of MAP4K4

A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity Find out more

Dual DNA-PK/AKT inhibition for the treatment of platinum-resistant cancer

Dual DNA-PK/AKT inhibition for the treatment of platinum-resistant cancer

Novel compounds with dual DNA-PK/AKT inhibitor activity for the treatment of platinum-resistant cancers. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...